U.S. markets close in 3 hours 23 minutes

AnaptysBio, Inc. (AN6.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
16.80-0.60 (-3.45%)
As of 6:00PM CEST. Market open.

AnaptysBio, Inc.

10421 Pacific Center Court
Suite 200
San Diego, CA 92121
United States
858 362 6295
http://www.anaptysbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees94

Key Executives

NameTitlePayExercisedYear Born
Mr. Hamza SuriaPres, CEO & Director573.54k3.57M1976
Mr. Eric J. LoumeauCOO & Gen. Counsel480.76kN/A1963
Mr. Dennis M. MulroyChief Financial OfficerN/AN/A1955
Ms. Beth MuellerSr. VP of HRN/AN/AN/A
Dr. Margaret MarinoSr. VP of Project ManagementN/AN/AN/A
Dr. Paul F. LizzulChief Medical OfficerN/AN/A1975
Mr. David McKeonVP & ControllerN/AN/A1972
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Corporate Governance

AnaptysBio, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 8. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.